Artivion develops and sells medical devices focused on treating diseases of the aorta, partnering with cardiac and vascular surgeons worldwide. Its main product lines include aortic stent grafts and hybrid devices, On-X mechanical heart valves, surgical sealants, and implantable cardiac and vascular human tissues. The company—formerly CryoLife—competes with a specialized aortic-centric portfolio rather than a broad general cardiology lineup, and markets products in more than 100 countries.
| Quarter | Revenue | YoY % | Earnings | YoY % |
|---|---|---|---|---|
| Q2 2025 | 113 | — | 1.3 | — |
| Q3 2025 | 113.4 | — | 6.5 | — |
| Q4 2025 | 116 | — | 2.4 | — |
| Q1 2026 | 116.3 | — | 1.4 | — |
| Q2 2026 | 125.8 | 11.3% | -13.5 | -1,104.8% |
All markets — KeepWinning global stock screener
Other companies on NYSE: Marcus & Millichap, Inc. (MMI), Sabine Royalty Trust (SBR), NCR Voyix Corporation (VYX), BigBear.ai Holdings, Inc. (BBAI), Ameresco, Inc. (AMRC), Teladoc Health, Inc. (TDOC)